The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Combination Chemotherapy in Advanced Adrenocortical Carcinoma
Open accessAbstract
BACKGROUND: Adrenocortical carcinoma is a rare cancer that has a poor response to cytotoxic treatment. METHODS: We randomly assigned 304 patients with advanced adrenocortical carcinoma to receive mitotane plus either a combination of etoposide (100 mg per square meter of body-surface area on days 2 to 4), doxorubicin (40 mg per square meter on day 1), and cisplatin (40 mg per square meter on days 3 and 4) (EDP) every 4 weeks or streptozocin (streptozotocin) (1 g on days 1 to 5 in cycle 1; 2 g on day 1 in subsequent cycles) every 3 weeks. Patients with disease progression received the alternative regimen as second-line therapy. The primary end point was overall survival. RESULTS: For first-line therapy, patients in the EDP-mitotane group had a significantly higher response rate than those in the streptozocin-mitotane group (23.2% vs. 9.2%, P<0.001) and longer median progression-free survival (5.0 months vs. 2.1 months; hazard ratio, 0.55; 95% confidence interval [CI], 0.43 to 0.69; P<0.001); there was no significant between-group difference in overall survival (14.8 months and 12.0 months, respectively; hazard ratio, 0.79; 95% CI, 0.61 to 1.02; P=0.07). Among the 185 patients who received the alternative regimen as second-line therapy, the median duration of progression-free survival was 5.6 months in the EDP-mitotane group and 2.2 months in the streptozocin-mitotane group. Patients who did not receive the alternative second-line therapy had better overall survival with first-line EDP plus mitotane (17.1 month) than with streptozocin plus mitotane (4.7 months). Rates of serious adverse events did not differ significantly between treatments. CONCLUSIONS: Rates of response and progression-free survival were significantly better with EDP plus mitotane than with streptozocin plus mitotane as first-line therapy, with similar rates of toxic events, although there was no significant difference in overall survival. (Funded by the Swedish Research Council and others; FIRM-ACT ClinicalTrials.gov number, NCT00094497.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Adjuvant Mitotane Treatment for Adrenocortical Carcinoma
Terzolo, M., Angeli, A., Fassnacht, M., Daffara, F., Tauchmanova, L., Conton, P. A., Rossetto, R., Buci, L., Sperone, P., Grossrubatscher, E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063360 · Cited by 764
Self-citationFassnacht, M., Johanssen, S., Quinkler, M., Bucsky, P., Willenberg, H. S., Beuschlein, F., Terzolo, M., Mueller, H., Hahner, S., Allolio, B., et al. (2009) · Cancer · doi:10.1002/cncr.24030 · Cited by 695
Self-citationIcard, P., Goudet, P., Charpenay, C., Andreassian, B., Carnaille, B., Chapuis, Y., Cougard, P., Henry, J., & Proye, C. (2001) · World Journal of Surgery · doi:10.1007/s00268-001-0047-y · Cited by 543
Golden, S. H., Robinson, K. A., Saldanha, I., Anton, B., & Ladenson, P. W. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2291 · Cited by 542
Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?
Kebebew, E., Reiff, E., Duh, Q., Clark, O. H., & McMillan, A. (2006) · World Journal of Surgery · doi:10.1007/s00268-005-0329-x · Cited by 451
Abiven, G., Coste, J., Groussin, L., Anract, P., Tissier, F., Legmann, P., Dousset, B., Bertagna, X., & Bertherat, J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2730 · Cited by 435
Management of patients with adrenal cancer: recommendations of an international consensus conference
Schteingart, D. E., Doherty, G. M., Gauger, P. G., Giordano, T. J., Hammer, G. D., Korobkin, M., & Worden, F. P. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.01029 · Cited by 421
Self-citationAdrenocortical carcinoma: a clinician’s update
Fassnacht, M., Libé, R., Kroiss, M., & Allolio, B. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.235 · Cited by 396
Self-citationHaak, H., Hermans, J., van de Velde, C., Lentjes, E., Goslings, B., Fleuren, G.-J., & Krans, H. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.183 · Cited by 329
Self-citationBerruti, A., Terzolo, M., Sperone, P., Pia, A., Della Casa, S., Gross, D. J., Carnaghi, C., Casali, P., Porpiglia, F., Mantero, F., et al. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.01025 · Cited by 308
Self-citationInterpreting quality of life data
Fayers, P. M. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00127-7 · Cited by 289
Adrenocortical cancer: pathophysiology and clinical management
Libè, R., Fratticci, A., & Bertherat, J. (2007) · Endocrine-Related Cancer · doi:10.1677/erc.1.01130 · Cited by 272
Baudin, E., Pellegriti, G., Bonnay, M., Penfornis, A., Laplanche, A., Vassal, G., & Schlumberger, M. (2001) · Cancer · doi:10.1002/1097-0142(20010915)92:6<1385::aid-cncr1461>3.0.co;2-2 · Cited by 239
Self-citationPrognostic parameters of metastatic adrenocortical carcinoma
Assié, G., Antoni, G., Tissier, F., Caillou, B., Abiven, G., Gicquel, C., Leboulleux, S., Travagli, J.-P., Dromain, C., Bertagna, X., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0706 · Cited by 236
Self-citationLughezzani, G., Sun, M., Perrotte, P., Jeldres, C., Alasker, A., Isbarn, H., Budäus, L., Shariat, S. F., Guazzoni, G., Montorsi, F., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.007 · Cited by 215
Khan, T. S., Imam, H., Juhlin, C., Skogseid, B., Gröndal, S., Tibblin, S., Wilander, E., Öberg, K., & Eriksson, B. (2000) · Annals of Oncology · doi:10.1023/a:1008377915129 · Cited by 183
Self-citationItalian Group for the Study of Adrenal Cancer, Berruti, A., Terzolo, M., Pia, A. R., Angeli, A., & Dogliotti, L. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981115)83:10<2194::aid-cncr19>3.0.co;2-3 · Cited by 176
Self-citationHermsen, I. G., Fassnacht, M., Terzolo, M., Houterman, S., den Hartigh, J., Leboulleux, S., Daffara, F., Berruti, A., Chadarevian, R., Schlumberger, M., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2676 · Cited by 173
Self-citationTreatment of Advanced Adrenocortical Carcinoma with Erlotinib plus Gemcitabine
Quinkler, M. O., Hahner, S., Wortmann, S., Johanssen, S., Adam, P., Ritte, C., Strasburger, C. J., Allolio, B., & Faßnacht, M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2564 · Cited by 154
Self-citationKroiss, M., Quinkler, M., Lutz, W. K., Allolio, B., & Fassnacht, M. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04214.x · Cited by 148
Self-citationBerruti, A., Sperone, P., Ferrero, A., Germano, A., Ardito, A., Priola, A. M., Francia, S. D., Volante, M., Daffara, F., Generali, D., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0918 · Cited by 146
Self-citationGross, D. J., Munter, G., Bitan, M., Siegal, T., Gabizón, A., Weitzen, R., Merimsky, O., Ackerstein, A., Salmon, A. Y., Sella, A., et al. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01124 · Cited by 136
Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma
Wortmann, S., Quinkler, M., Ritter, C., Kroiss, M., Johanssen, S., Hahner, S., Allolio, B., & Fassnacht, M. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0804 · Cited by 133
Self-citationAbraham, J., Bakke, S., Rutt, A., Meadows, B., Merino, M. J., Alexander, R. H., Schrump, D. S., Bartlett, D., Choyke, P. L., Robey, R. W., et al. (2002) · Cancer · doi:10.1002/cncr.10487 · Cited by 129
Self-citationMitotane has a strong and a durable inducing effect on CYP3A4 activity
van Erp, N. P., Guchelaar, H.-J., Ploeger, B. A., Romijn, J. A., Hartigh, J. D., & Gelderblom, H. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-0956 · Cited by 118
Self-citationWilliamson, S. K., Lew, D. L., Miller, G. J., Balcerzak, S. P., Baker, L. H., & Crawford, E. D. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000301)88:5<1159::aid-cncr28>3.0.co;2-r · Cited by 117
Contemporary Management of Adrenocortical Carcinoma
Zini, L., Porpiglia, F., & Faßnacht, M. (2011) · European Urology · doi:10.1016/j.eururo.2011.07.062 · Cited by 117
Bukowski, R. M., Wolfe, M., Levine, H. S., Crawford, D., Stephens, R. L., Gaynor, E. R., & Harker, W. G. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.1.161 · Cited by 110
New targets and therapeutic approaches for endocrine malignancies☆
Fassnacht, M., Kreissl, M. C., Weismann, D., & Allolio, B. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.03.013 · Cited by 107
Self-citationMalandrino, P., Ghuzlan, A. A., Castaing, M., Young, J., Caillou, B., Travagli, J., Elias, D. M., de Baère, T., Dromain, C., Paci, A., et al. (2010) · Endocrine Related Cancer · doi:10.1677/erc-09-0341 · Cited by 62
Self-citationTherapeutic Management of Advanced Adrenocortical Carcinoma: What Do We Know in 2011?
Baudin, É., Leboulleux, S., Ghuzlan, A. A., Chougnet, C., Young, J., Deandreis, D., Dumont, F., Dechamps, F., Caramella, C., Chanson, P., et al. (2011) · Hormones and Cancer · doi:10.1007/s12672-011-0094-2 · Cited by 47
Self-citationEmerging drugs for adrenocortical carcinoma
Berruti, A., Ferrero, A., Sperone, P., Daffara, F., Reimondo, G., Papotti, M. G., Dogliotti, L., Angeli, A., & Terzolo, M. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.13.3.497 · Cited by 40
Self-citation
Cited by
Fassnacht, M., Dekkers, O. M., Else, T., Baudin, E., Berruti, A., de Krijger, R. R., Haak, H. R., Mihai, R., Assie, G., & Terzolo, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0608 · Cited by 961
Self-citationElse, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892
Integrated genomic characterization of adrenocortical carcinoma
Assié, G., Letouzé, E., Fassnacht, M., Jouinot, A., Luscap, W., Barreau, O., Omeiri, H., Rodriguez, S., Perlemoine, K., René-Corail, F., et al. (2014) · Nature Genetics · doi:10.1038/ng.2953 · Cited by 732
Self-citationNeuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Shah, M. H., Goldner, W. S., Benson, A. B., Bergsland, E., Blaszkowsky, L. S., Brock, P., Chan, J., Das, S., Dickson, P. V., Fanta, P., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0032 · Cited by 619
Croissant, J. G., Fatieiev, Y., Almalik, A., & Khashab, N. M. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201700831 · Cited by 594
Metadata
- Authors
- Fassnacht, M., Terzolo, M., Allolio, B., Baudin, E., Haak, H., Berruti, A., Welin, S., Schade-Brittinger, C., Lacroix, A., Jarzab, B., Sorbye, H., Torpy, D. J., Stepan, V., Schteingart, D. E., Arlt, W., Kroiss, M., Leboulleux, S., Sperone, P., Sundin, A., Hermsen, I., Hahner, S., Willenberg, H. S., Tabarin, A., Quinkler, M., de la Fouchardière, C., Schlumberger, M., Mantero, F., Weismann, D., Beuschlein, F., Gelderblom, H., Wilmink, H., Sender, M., Edgerly, M., Kenn, W., Fojo, T., Müller, H.-H., & Skogseid, B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-06-07
- Volume
- 366
- Issue
- 23
- Pages
- 2189-2197
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1967352082
- Cited by
- 873
- References
- 33
- FWCI
- 62.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.